USFDA issues import alert on Ranbaxys Mohali unit

Import alert issued by USFDA on Ranbaxy's Mohali plant could not only be negative for the stock but according to the analyst community Ranbaxy could be on its last legs for having a good strong base in the US.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney SME Special
moneycontrol.com

Home » News » CNBC-TV18 Comments

Sep 17, 2013, 09.02 AM | Source: CNBC-TV18

USFDA issues import alert on Ranbaxy's Mohali unit

Import alert issued by USFDA on Ranbaxy's Mohali plant could not only be negative for the stock but according to the analyst community Ranbaxy could be on its last legs for having a good strong base in the US.

Like this story, share it with millions of investors on M3

USFDA issues import alert on Ranbaxys Mohali unit

Import alert issued by USFDA on Ranbaxy's Mohali plant could not only be negative for the stock but according to the analyst community Ranbaxy could be on its last legs for having a good strong base in the US.

Post Your Comments

Share Cancel

Ekta Batra (more)

Markets Anchor & Financial Analyst, CNBC-TV18 |

The US Food and Drug Administration (USFDA) issued import alert on Ranbaxy Laboratories 's Mohali Unit reports CNBC-TV18’s Ekta Batra.

This could be an extreme negative for Ranbaxy and according to the analyst community Ranbaxy could be on its last legs for having a good strong base in the US.

Also read: Drugmakers draw more FDA scrutiny as US imports rise

After the problems at Paonta Sahib and Dewas, the USFDA now has a problem per se with its unit at Mohali.

Mohali being a new plant, manufacturing wasn’t at full scale but most of the new drugs by the company were slated to be actually manufactured there. There is yet more clarity required from the company itself in terms of what will happen to all of their big ticket drugs, which were expected to be launched especially in Q4 CY13. 

Key Points

There was already Form 483, which was issued for Mohali. This means there were certain manufacturing practices which the US FDA had already pointed out and the company had time to comply to the problems US FDA had bought up.

However, since Ranbaxy could not comply to with those issues the 483 has now converted to an import alert.

The stock closed at around Rs 319, down 30 percent from its previous closing.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
USFDA issues import alert on Ranbaxys Mohali unit

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login